| Autor: |
Miller ME; Indiana University School of Medicine, Indianapolis, IN, USA.; Department of Adult Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IA, USA., Rahim MQ; Indiana University School of Medicine, Indianapolis, IN, USA.; Division Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA., Coven SL; Indiana University School of Medicine, Indianapolis, IN, USA.; Division Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA.; Cancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IA, USA., Jacob SA; Indiana University School of Medicine, Indianapolis, IN, USA.; Division Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA.; Center for Pediatric and Adolescent Comparative Effectiveness Research, Indianpolis, IA, USA., Zimet GD; Cancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IA, USA.; Division of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA., Meagher CG; Division of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA., Ott MA; Division of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IA, USA.; IU Center for Bioethics, Indiana University School of Medicine, Indianapolis, IA, USA. |
| Abstrakt: |
Rates of Human papilloma virus (HPV) vaccination among pediatric survivors of cancer and patients with sickle cell disease are lower than the national average. While recent attention has focused on patient HPV vaccine hesitancy and refusal, less is known about provider-level and system-level barriers to vaccinations in pediatric hematology/oncology (PHO) populations. Applying thematic analysis to qualitative interviews with 20 pediatric hematology/oncology physicians and nurse practitioners, we examine their views regarding HPV vaccination, with a focus on access and barriers to providing HPV vaccination in PHO practices. Results demonstrated that despite 90% of interviewees supporting HPV vaccination in their population, the number of pediatric hematology/oncology providers who reported that they counsel about HPV or provide HPV vaccination was 45%, even in stem cell and sickle cell clinics, where other childhood vaccines are commonly provided. Clinicians identified provider-level, clinic-level, and system-level barriers to giving the HPV vaccination, including but not limited to time/flow constraints, lack of resources, and continued education regarding the HPV vaccine. These barriers impede the ability for pediatric hematology/oncology providers to counsel and provide HPV vaccination to this specialized population. |
